A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Registration Number
- NCT01379560
- Lead Sponsor
- Sucampo Pharma Americas, LLC
- Brief Summary
The purpose of this study is to determine the pharmacodynamics of ocular blood flow measurements with multiple drop unoprostone isopropyl administration versus placebo in subjects with dry age-related macular degeneration (AMD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- Age ≥ 50 years at screening
- Ametropy ≤ 3 diopters
- Clear ocular media
- Visual acuity in the study eye > 20/40
Read More
Exclusion Criteria
- Presence of any ocular condition in the study eye (other than AMD) that may progress during the course of the study and could affect central vision, or other ocular conditions that may be a confounding factor in this study
- Blood donation during the previous 3 weeks
- Current smoker or a history of smoking within 5 years of enrollment
- Treatment with protocol-specified prohibited concomitant medications
- Prior exposure to Rescula (unoprostone isopropyl) and or a known sensitivity to any of the components of the study medication (e.g. benzalkonium chloride)
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description unoprostone isopropyl (3 drop) unoprostone isopropyl - unoprostone isopropyl (2 drop) unoprostone isopropyl -
- Primary Outcome Measures
Name Time Method Change in choroidal blood flow In total 6 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Medical University of Vienna
🇦🇹Vienna, Austria